Subscribe to the Daily PV Brief for breaking drug safety news, regulatory updates, and pharmacovigilance insights.
Daily News and Intelligence for the Pharmacovigilance Industry
Stay informed with timely coverage of drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, compliance trends, and career insights from across the global PV landscape.
FDA Requires Vitamin B6 Deficiency Warning for Carbidopa/Levodopa
FDA is requiring updated labeling for carbidopa/levodopa products to warn about vitamin B6 deficiency and related seizures, adding a new monitoring point for Parkinson’s treatment.
Today in PV
A quick scan of the latest stories, safety concerns, regulatory developments, and industry signals every pharmacovigilance professional should know today.
Explore Coverage
Browse the key areas shaping pharmacovigilance today, from global regulatory updates to safety signals, compliance trends, AI, and career growth.
Regulatory Updates
Track key developments from FDA, EMA, MHRA, WHO, NAFDAC, Health Canada, TGA, SAHPRA, and other health authorities.
Inspections & Compliance
Stay current on inspection readiness, CAPAs, SOP expectations, audit trends, and the compliance issues shaping PV systems.
Explainers
Clear, practical breakdowns of PV concepts, industry terms, reporting frameworks, and regulatory changes.
Careers
Insights for professionals building or advancing careers in pharmacovigilance, drug safety, compliance, and related functions.
Safety Signals
Follow emerging risks, label changes, recalls, medication errors, and other safety issues that matter in real-world pharmacovigilance.
AI & Digital PV
Explore how artificial intelligence, automation, and digital tools are influencing case processing, signal detection, and safety operations.
Latest News
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam. Aque ipsa quae ab illo inventore veritatis. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accus antium doloremque.
UK Trial Safety Reporting in 2026: What Inspection-Ready Teams Should Get Right
The UK’s updated clinical-trial framework increases the urgency of getting safety-event collection, verification, and reporting right before implementation goes live.
FDA’s 10 Good AI Practice Principles: What They Mean for PV Teams
FDA’s new Good AI Practice principles are not PV-specific, but they point clearly toward what responsible AI use in pharmacovigilance will require: governance, documentation, context of use, and lifecycle oversight.
Beyond FAERS: How FDA’s AEMS Is Expanding Digital Safety Surveillance
FDA’s AEMS is not just a public dashboard refresh. It is a broader platform for integrating adverse event reports, complaints, misconduct reports, and whistleblower submissions across FDA centers.
Patent Expirations Are Pushing Biopharma Toward a Tougher 2026 — Why PV Teams Should Pay Attention
Patent expirations and slower growth forecasts are putting pressure on biopharma in 2026. Here’s why pharmacovigilance teams should pay attention.
MHRA Strengthens Warnings for Gabapentinoids, Benzodiazepines and Z-Drugs
This MHRA action shows how regulators use postmarketing evidence not only to assess risk, but to improve how risk is explained, understood, and acted on by both clinicians and patients.
What the FDA’s New AEMS Signal Page Means for Pharmacovigilance Teams
The new AEMS signal page is a reminder that signal detection is not only an internal company activity. It is also a visible regulatory process. Teams that understand what the page is — and what it is not — will be better positioned to interpret FDA safety intelligence correctly.
Featured Posts
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Contact us
Email Us
editor@pvwatchdaily.com